What is the strategic significance of Novonesis acquiring Meihua’s fermentation facility in Rayong, Thailand?

The acquisition strengthens Novonesis’ production footprint in Southeast Asia and supports its GROW strategy by enhancing a resilient and responsive global supply network for long-term growth. The facility—equipped with fermentation capabilities—will be expanded to produce human milk oligosaccharides (HMO) and is expected to become commercially operational in 2027. Novonesis plans further investment in the site over the coming years to maximize its potential and establish a strong operational setup.

How does this acquisition fit into Novonesis’ broader global expansion and capital expenditure plans?

This acquisition is one of several recent investments—alongside expansions in Franklinton (North Carolina), West Allis (Wisconsin), Taicang (China), and Araucaria (Brazil)—aimed at strengthening Novonesis’ global production resilience. The company expects to increase growth-focused capital expenditure through its current strategy period toward 2030 to meet rising demand for biosolutions among customers and consumers.

Novonesis Acquires Meihua’s Fermentation Facility in Thailand for $50M

Apr 16, 2026

Novonesis has agreed to acquire Meihua Holdings' fermentation facility in Rayong, Thailand, for approximately $50 million to expand its Southeast Asian footprint. The site will support human milk oligosaccharide production and is expected to be commercially operational by 2027.

chemweek

2025-11-06

Novonesis Upgrades Organic Sales Growth Guidance, Lowers Margin Expectations

2025-11-19

Novonesis, Thyssenkrupp Jointly Launch Enzymatic Fat-Splitting Process

2026-02-05

Novonesis Achieves Renewable Electricity Target for Global Operations

2026-02-25

Novonesis Expects Sales Growth and Margin Expansion in 2026

2026-04-16

Novonesis Acquires Meihua’s Fermentation Facility in Thailand for $50M